Efficacy and safety of abatacept in RA patients in daily clinical practice: An retrospective observational study Orencia as Biological Intensive Treatment for RA
Not Applicable
Recruiting
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000008578
- Lead Sponsor
- niversity of Occupational and Environmental Health, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are inadequate by investigator's decision.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients with structural remission (modified total Sharp score(mTSS) ≤0) at week 24,52,104.
- Secondary Outcome Measures
Name Time Method Proporon (Simplified Disease Activity Index:SDAI≤3.3) or with functional remission (Health Assessment Questionaire:HAQ ≤0.5) at week 24, 52,104 Disease Activity Score:DAS28 CRP/SDAItion of patients with clinical remissi